News and Announcements
FocusStart Advances to 2017 MN Cup Semi-Finals
- Published July 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
FocusStart has advanced in the Minnesota-based entrepreneurs, inventors and innovators to the semi-finals of the 2017 competition. In its thirteenth year, the MN Cup is giving away $450,000 in seed money, mentorship opportunities with industry leaders, exclusive event access, business plan feedback, networking opportunities with potential investors and media exposure.
KEY TAKEAWAYS:
- FocusStart Respiratory is developing a complete inhaled medication management system to improve patient adherence.
- The company has an innovative health IT solution consists of an inhaler device add-on component that allows communication with smart devices, a patient companion app and a clinician app.
- The add-on component tracks when/where/how the inhaler is used, and measures inhalation and exhalation; and when used with the companion app, the system provides real-time training for proper inhaler use, and supports proper remote lung function testing.
300 million patients suffer from asthma world-wide, morbidity, mortality and healthcare costs are increasing due to poor asthma management. To address these problems, FocusStart have developed Spirit, a comprehensive health IT disease management solution composed of a inhaler add-on medical device connected to patient and provider software applications. This solution will enable better asthma control, and thus reduce healthcare utilization and healthcare costs.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
